-

Trialbee and uMotif Simplify and Expand Patient Access to Global Clinical Trials

Integrated platform from industry leaders will remove complexities in the patient journey to benefit all clinical trial stakeholders

CHAPEL HILL, N.C. & MALMÖ, Sweden & LONDON--(BUSINESS WIRE)--The increasing need for speed and efficiency in clinical research has created more urgency to streamline and simplify the patient journey. Trialbee, a patient matching and enrolment platform, and uMotif, a patient-centric data capture provider, are partnering to improve the patient experience and improve trial accessibility globally.

The new partnership streamlines the end-to-end patient journey through a lightweight, data-driven solution that removes the need for multiple apps or systems. The companies’ integrated platforms simplify trial activities from initial awareness through enrollment and data collection during study conduct and close-out, optimising the patient experience to achieve greater compliance for protocol requirements and increased retention.

“Technology is changing the way clinical trials are run, presenting new opportunities to expand patient access, especially among historically underrepresented patient groups, and bring life saving drugs and devices to market efficiently and effectively,” says Matt Walz, CEO of Trialbee. “Through this partnership, Trialbee and uMotif are transforming clinical trials to benefit global patients, trials sponsors, CROs, investigative sites and other stakeholders.”

Patients are digitally matched to study protocols via Trialbee HIVE™, the real-world data (RWD) driven patient matching platform that accelerates recruitment using global data assets, look-alike modelling, and a scalable nurse qualification process. Qualified, study-ready patients are then consented at-site or remotely through the Trialbee platform, which is integrated with uMotif’s application.

Once enrolled, patients use the engaging uMotif app to capture large volumes of high quality ePRO, eDiary and symptom data in real-time throughout the duration of a trial. Patients are empowered to manage and collect their data in an easy-to-use application, while sponsors receive a better understanding of patient symptoms and behavior.

“uMotif’s collaboration with Trialbee supports our mission to provide a more seamless experience for patients and clinical trial professionals including sponsors, CROs and sites. Our human-centred and design-led approach means our technology powers the capture of large volumes of high-quality patient data, via BYOD and/or provisioned devices. Empowering patients to capture their data remotely through a Decentralized Clinical Trial approach removes site burden and potential bias, supporting more efficient trials,” said Bruce Hellman, CEO of uMotif.

About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.

About uMotif
uMotif's mission is to put patients at the centre of clinical research. Designed with patients for patients, the uMotif patient-centric eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture eConsent and large volumes of ePRO, symptom, and wearable device data. umotif.com

Contacts

Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com

Sally Vernon
For uMotif
Sally.vernon@umotif.com

Trialbee


Release Versions

Contacts

Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com

Sally Vernon
For uMotif
Sally.vernon@umotif.com

Social Media Profiles
More News From Trialbee

Trialbee Adds Marketing VP Kristopher Sarajian to Proven Leadership Team Amid Surge in Demand for the Honey™ Enrollment Platform

CHAPEL HILL, N.C. & MALMO, Sweden--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced the addition of Kristopher Sarajian as Vice President of Marketing to its already impressive leadership team. The appointment comes as Trialbee accelerates its momentum and growth in demand for the Honey™ enrollment platform and expert patient matching powered by real-world data. In this role, Sarajian will be responsible f...

Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation

CHAPEL HILL, N.C. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate, whose NOWINCLUDED™ community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED™ community through Trialbee Honey™ Omnichannel. Trialbee will work with Acclinate...

Trialbee Announces Trialbee Honey™ Omnichannel, Real-Time Patient Recruitment Tracking for Multiple Recruitment Sources at CNS Summit 2022

CHAPEL HILL, N.C. & MALMO, Sweden--(BUSINESS WIRE)--Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, will introduce Trialbee Honey™ Omnichannel, a powerful multichannel approach to global patient recruitment, at CNS Summit on Nov. 17-20 in Boca Raton, Florida. Honey Omnichannel enables tracking for multiple recruitment sources, offering sponsors and CROs a simplified patient journey into the study with consistent messaging and pre-qualifi...
Back to Newsroom